Literature DB >> 9702853

Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graft-versus-host disease in mice.

A Nonomura1, N Kono, H Minato, Y Nakanuma.   

Abstract

Experimental graft-versus-host disease (GVHD) across minor histocompatibility antigens was developed by injecting spleen and bone marrow cells (9:1) of congenic B10.D2 mice into sublethally irradiated BALB/c mice, and the histologic features of the liver were studied for up to 14 months after transplantation. Both intrahepatic and extrahepatic bile ducts were severely involved in the GVHD process and showed features of non-suppurative cholangitis. Inflammatory cells, mainly lymphocytes, abutted the bile ducts and infiltrated into the duct epithelial layer together with a variety of degenerative changes in the epithelial cells. The peak inflammatory activity occurred about 2-3 weeks after transplantation. Thereafter, the inflammatory cell infiltration around the bile ducts and in the bile duct epithelial layer gradually became reduced in severity, although the infiltration persisted during the entire 14 month observation period. Periductal and duct wall fibroplasia began about 1 week after transplantation and gradually progressed. After 2-3 months post-transplantation, distinct ductal and periductal fibrosis of both intrahepatic and extrahepatic bile ducts was observed. This histologic feature resembled that of primary sclerosing cholangitis (PSC). These results suggest that PSC lesions might develop as a result of chronic cellular immunologic mechanisms in GVHD across minor histocompatibility barriers.

Entities:  

Mesh:

Year:  1998        PMID: 9702853     DOI: 10.1111/j.1440-1827.1998.tb03927.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

Review 1.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

Review 2.  Imaging of late complications of cancer therapy in children.

Authors:  Susan C Shelmerdine; Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2016-12-01

3.  Novel model of antigen-specific induction of bile duct injury.

Authors:  James Buxbaum; Peiqing Qian; Ciera Khuu; Benjamin L Shneider; David I Daikh; M Eric Gershwin; Paul M Allen; Marion G Peters
Journal:  Gastroenterology       Date:  2006-10-14       Impact factor: 22.682

Review 4.  Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Peter Fickert
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

6.  Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.

Authors:  Saori Yaguchi; Yoko Ogawa; Shigeto Shimmura; Tetsuya Kawakita; Shin Hatou; Shingo Satofuka; Shigeru Nakamura; Toshihiro Imada; Hideyuki Miyashita; Satoru Yoshida; Tomonori Yaguchi; Yoko Ozawa; Takehiko Mori; Shinichiro Okamoto; Yutaka Kawakami; Susumu Ishida; Kazuo Tsubota
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.